Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2014-10 Issue:10 Volume:13 Page:977-986
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Miller Aaron E,Wolinsky Jerry S,Kappos Ludwig,Comi Giancarlo,Freedman Mark S,Olsson Tomas P,Bauer Deborah,Benamor Myriam,Truffinet Philippe,O'Connor Paul W

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference22 articles.

1. Clinically isolated syndromes;Miller;Lancet Neurol,2012

2. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials;Bates;Neurology,2011

3. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group;Jacobs;N Engl J Med,2000

4. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study;Comi;Lancet,2001

5. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial;Filippi;Lancet,2004

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis treatments a review of current biomedical engineering approaches;Biomaterials;2025-02

2. A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

3. Long‐Term Safety of Teriflunomide in Multiple Sclerosis Patients: Results of Prospective Comparative Studies in Three European Countries;Pharmacoepidemiology and Drug Safety;2024-07

4. Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data;Neurology and Therapy;2024-05-16

5. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS;Multiple Sclerosis Journal;2024-04-15